autologous PRAME-targeting TCR-engineered T cells IMA203

{
  "id": "MLC-T-ONC-011752",
  "term": "autologous PRAME-targeting TCR-engineered T cells IMA203",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous PRAME-targeting TCR-engineered T cells IMA203 specifically recognize and bind to PRAME expressed on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the PRAME-expressing cancer cells. PRAME is overexpressed by a variety of cancer cell types.",
  "synonyms": [
    "ACTengine IMA203",
    "autologous T-cell receptor-engineered T cells IMA203",
    "IMA203 autologous T lymphocytes",
    "IMA203 T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-prame-targeting-tcr-engineered-t-cells-ima203/"
}